Status:
WITHDRAWN
Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of pati...
Detailed Description
The current gold standard for the treatment of proliferative diabetic retinopathy is panretinal photocoagulation. However, it is a treatment that results in significant discomfort to the patient, caus...
Eligibility Criteria
Inclusion
- symmetric proliferative diabetic retinopathy without high risk characteristics
- age 18 years or older
- patient consent
Exclusion
- heart attack or cerebrovascular attack
- only eye
- retinal detachment
- vitreous haemorrhage
- previous treatment for diabetic retinopathy
- media opacities that preclude visualization of the fundus
- pregnancy
- inability to understands the implications of the protocol
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00347698
Start Date
March 1 2006
End Date
August 1 2007
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociación para Evitar la Ceguera en México
Mexico City, D. F, Mexico, 04030